Hypofractionated stereotactic body radiation therapy for elderly patients with stage IIB–IV nonsmall cell lung cancer who are ineligible for or refuse other treatment modalities
Sana D Karam,1 Zachary D Horne,2 Robert L Hong,2 Don McRae,2 David Duhamel,3 Nadim M Nasr2 1Department of Radiation Oncology, University of Colorado, Denver, CO, USA; 2Department of Radiation Oncology, 3Department of Pulmonary/Critical Care Medicine, Virginia Hospital Center, Arlington, VA, USA Ob...
Guardado en:
| Autores principales: | , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2014
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/947a5c7b71054644bd3998088d4240e2 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:947a5c7b71054644bd3998088d4240e2 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:947a5c7b71054644bd3998088d4240e22021-12-02T00:29:56ZHypofractionated stereotactic body radiation therapy for elderly patients with stage IIB–IV nonsmall cell lung cancer who are ineligible for or refuse other treatment modalities1179-2728https://doaj.org/article/947a5c7b71054644bd3998088d4240e22014-10-01T00:00:00Zhttp://www.dovepress.com/hypofractionated-stereotactic-body-radiation-therapy-for-elderly-patie-peer-reviewed-article-LCTThttps://doaj.org/toc/1179-2728 Sana D Karam,1 Zachary D Horne,2 Robert L Hong,2 Don McRae,2 David Duhamel,3 Nadim M Nasr2 1Department of Radiation Oncology, University of Colorado, Denver, CO, USA; 2Department of Radiation Oncology, 3Department of Pulmonary/Critical Care Medicine, Virginia Hospital Center, Arlington, VA, USA Objective: In elderly patients with stage IIB–IV nonsmall cell lung cancer who cannot tolerate chemotherapy, conventionally fractionated radiotherapy is the treatment of choice. We present our experience with hypofractionated stereotactic body radiation therapy (SBRT) in the treatment of this patient population. Methods: Thirty-three patients with a median age of 80 years treated with fractionated SBRT were retrospectively analyzed. Most patients were smokers and had preexisting lung disease and either refused treatment or were ineligible. A median prescribed dose of 40 Gy was delivered to the prescription isodose line over a median of five treatments. The majority of patients (70%) did not receive chemotherapy. Results: With a median follow-up of 9 months (range: 4–40 months), the actuarial median overall survival (OS) and progression-free survival were 12 months for both. One year actuarial survival outcomes were 75%, 58%, 44%, and 48% for local control, regional control, progression-free survival, and OS, respectively. Increased volume of disease was a statistically significant predictor of worse OS. Three patients developed a grade 1 cough that peaked 3 weeks after treatment and resolved within 1 month. One patient developed grade 1 tracheal mucositis and three patients developed grade 1 pneumonitis. Both resolved 6 weeks after treatment. Three patients died within the first month of treatment, but the cause of death did not appear to be related to the treatment. Conclusion: Hypofractionated SBRT is a relatively safe and convenient treatment option for elderly patients with inoperable stage IIB–IV nonsmall cell lung cancer. However, given the small sample size and the heterogeneity of the patient population, larger studies are needed before adopting this treatment option into clinical practice. Keywords: stereotactic body radiation therapy, CyberKnife, stage IIB, stage IIIA, stage IV, nodal, chemotherapyKaram SDHorne ZDHong RLMcRae DDuhamel DNasr NMDove Medical PressarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENLung Cancer: Targets and Therapy, Vol 2014, Iss default, Pp 59-66 (2014) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 |
| spellingShingle |
Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Karam SD Horne ZD Hong RL McRae D Duhamel D Nasr NM Hypofractionated stereotactic body radiation therapy for elderly patients with stage IIB–IV nonsmall cell lung cancer who are ineligible for or refuse other treatment modalities |
| description |
Sana D Karam,1 Zachary D Horne,2 Robert L Hong,2 Don McRae,2 David Duhamel,3 Nadim M Nasr2 1Department of Radiation Oncology, University of Colorado, Denver, CO, USA; 2Department of Radiation Oncology, 3Department of Pulmonary/Critical Care Medicine, Virginia Hospital Center, Arlington, VA, USA Objective: In elderly patients with stage IIB–IV nonsmall cell lung cancer who cannot tolerate chemotherapy, conventionally fractionated radiotherapy is the treatment of choice. We present our experience with hypofractionated stereotactic body radiation therapy (SBRT) in the treatment of this patient population. Methods: Thirty-three patients with a median age of 80 years treated with fractionated SBRT were retrospectively analyzed. Most patients were smokers and had preexisting lung disease and either refused treatment or were ineligible. A median prescribed dose of 40 Gy was delivered to the prescription isodose line over a median of five treatments. The majority of patients (70%) did not receive chemotherapy. Results: With a median follow-up of 9 months (range: 4–40 months), the actuarial median overall survival (OS) and progression-free survival were 12 months for both. One year actuarial survival outcomes were 75%, 58%, 44%, and 48% for local control, regional control, progression-free survival, and OS, respectively. Increased volume of disease was a statistically significant predictor of worse OS. Three patients developed a grade 1 cough that peaked 3 weeks after treatment and resolved within 1 month. One patient developed grade 1 tracheal mucositis and three patients developed grade 1 pneumonitis. Both resolved 6 weeks after treatment. Three patients died within the first month of treatment, but the cause of death did not appear to be related to the treatment. Conclusion: Hypofractionated SBRT is a relatively safe and convenient treatment option for elderly patients with inoperable stage IIB–IV nonsmall cell lung cancer. However, given the small sample size and the heterogeneity of the patient population, larger studies are needed before adopting this treatment option into clinical practice. Keywords: stereotactic body radiation therapy, CyberKnife, stage IIB, stage IIIA, stage IV, nodal, chemotherapy |
| format |
article |
| author |
Karam SD Horne ZD Hong RL McRae D Duhamel D Nasr NM |
| author_facet |
Karam SD Horne ZD Hong RL McRae D Duhamel D Nasr NM |
| author_sort |
Karam SD |
| title |
Hypofractionated stereotactic body radiation therapy for elderly patients with stage IIB–IV nonsmall cell lung cancer who are ineligible for or refuse other treatment modalities |
| title_short |
Hypofractionated stereotactic body radiation therapy for elderly patients with stage IIB–IV nonsmall cell lung cancer who are ineligible for or refuse other treatment modalities |
| title_full |
Hypofractionated stereotactic body radiation therapy for elderly patients with stage IIB–IV nonsmall cell lung cancer who are ineligible for or refuse other treatment modalities |
| title_fullStr |
Hypofractionated stereotactic body radiation therapy for elderly patients with stage IIB–IV nonsmall cell lung cancer who are ineligible for or refuse other treatment modalities |
| title_full_unstemmed |
Hypofractionated stereotactic body radiation therapy for elderly patients with stage IIB–IV nonsmall cell lung cancer who are ineligible for or refuse other treatment modalities |
| title_sort |
hypofractionated stereotactic body radiation therapy for elderly patients with stage iib–iv nonsmall cell lung cancer who are ineligible for or refuse other treatment modalities |
| publisher |
Dove Medical Press |
| publishDate |
2014 |
| url |
https://doaj.org/article/947a5c7b71054644bd3998088d4240e2 |
| work_keys_str_mv |
AT karamsd hypofractionatedstereotacticbodyradiationtherapyforelderlypatientswithstageiibndashivnonsmallcelllungcancerwhoareineligiblefororrefuseothertreatmentmodalities AT hornezd hypofractionatedstereotacticbodyradiationtherapyforelderlypatientswithstageiibndashivnonsmallcelllungcancerwhoareineligiblefororrefuseothertreatmentmodalities AT hongrl hypofractionatedstereotacticbodyradiationtherapyforelderlypatientswithstageiibndashivnonsmallcelllungcancerwhoareineligiblefororrefuseothertreatmentmodalities AT mcraed hypofractionatedstereotacticbodyradiationtherapyforelderlypatientswithstageiibndashivnonsmallcelllungcancerwhoareineligiblefororrefuseothertreatmentmodalities AT duhameld hypofractionatedstereotacticbodyradiationtherapyforelderlypatientswithstageiibndashivnonsmallcelllungcancerwhoareineligiblefororrefuseothertreatmentmodalities AT nasrnm hypofractionatedstereotacticbodyradiationtherapyforelderlypatientswithstageiibndashivnonsmallcelllungcancerwhoareineligiblefororrefuseothertreatmentmodalities |
| _version_ |
1718403690427056128 |